Study Overview: This study checks if a medicine called APG777 is safe and works well for people with atopic dermatitis (AD), a skin condition causing itchy and inflamed skin. The study is for those who have finished a previous APG777 study. It’s a double-blind study, meaning neither the doctors nor the participants will know who is getting the actual medicine or a placebo (a harmless pill). The study has three parts: screening, extended treatment, and post-treatment follow-up.
- Duration: The study will have multiple visits over a long period.
- Eligibility: Only for those who completed the previous APG777 study without major issues.
- Risks: Those who had side effects in the earlier study might not qualify.
Participants must keep using their regular non-prescription moisturizer. The study aims to find out if long-term use of APG777 is beneficial without causing harm. More rules apply to decide who can join.
How understandable was the trial content above?
Hard to understand
Easy to understand